Investigators examined survival outcomes and recurrence patterns by pathologic nodal status in patients with upper tract urothelial carcinoma (UTUC) receiving neoadjuvant chemotherapy.

Total neoadjuvant therapy demonstrates consistent real-world efficacy across regimens in patients with locally advanced ...

Tislelizumab combined with chemotherapy shows promising antitumor activity in advanced cervical cancer, achieving high response rates and manageable safety profiles.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Triple-negative breast cancer (TNBC) comprises 10–15% of all breast cancers. It is a very heterogeneous disease, ...

Announcing a new article publication for BIO Integration journal. Imbalances in the intestinal microbiome are closely ...

Over the last decade, there has been a major shift in the up-front treatment of advanced epithelial ovarian cancer (EOC) in the United States, with a substantial decline in primary cytoreduction ...

"PanTher Therapeutics launches second trial for chemotherapy patch" was originally created and published by Medical Device Network, a GlobalData owned brand.

Select patients with breast cancer who experience pathologic complete response to neoadjuvant systemic therapy and undergo radiotherapy may be able to forego breast surgery, according to study ...

Adding nivolumab to neoadjuvant chemotherapy significantly improved 5-year overall survival among patients with resectable non-small cell lung cancer (NSCLC), according to findings from a phase 3 ...

Neotorch—shedding a light on neoadjuvant chemo-immunotherapy in non-small cell lung cancer (NSCLC)? Background. Historically, only 30% of patients diagnosed with NSCLC have resectable disease ...